Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient's seated systolic BP (SeSBP) will be greater than or equal to 95th percentile for gender and height-for- age, or greater than or equal to 90th percentile if the patient is diabetic, or has glomerular kidney disease, or has a family history of hypertension.~* Negative for hepatitis B and C~* Negative for HIV~Exclusion Criteria:~* Patient should not have serious other conditions that could interfere with the analysis of the results or that could interfere with the well-being of the patient in the trial.~* Known sensitivity to olmesartan medoxomil~* Taking prohibited medication~* Consumed greater than 180 mg of caffeine daily~* Malignant hypertension~* History of congestive heart failure, cardiomyopathy, or obstructive valve disease~* Renal transplant within the previous 6 months~* Severe nephritic syndrome not in remission

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Period 2 (Type: EXPERIMENTAL): For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old.
- Period 3 (Type: EXPERIMENTAL): Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
- Period 4 (Type: EXPERIMENTAL): Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).